Are you Dr. Sahovic?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 32 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4815 Liberty Ave
Suite Gr70
Pittsburgh, PA 15224Phone+1 412-578-4355Fax+1 412-605-6538
Summary
- Dr. Entezam Sahovic, MD is an oncologist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and South Carolina. He is affiliated with West Penn Hospital and Forbes Hospital.
Education & Training
- Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 1984 - 1987
- MedStar Health/Georgetown-Washington Hospital CenterFellowship, Hematology and Medical Oncology, 1983 - 1984
- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1980 - 1983
- University of Sarajevo FOMClass of 1978
Certifications & Licensure
- SC State Medical License 1985 - 2017
- PA State Medical License 2006 - 2016
Clinical Trials
- Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy Start of enrollment: 2007 Oct 01
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Publications & Presentations
PubMed
- 57 citationsRole for Aldehyde Dehydrogenase in Survival of Progenitors for Murine Blast Cell Colonies after Treatment with 4-Hydroperoxycyclophosphamide in VitroEntezam A. Sahovic, Michael Colvin, John Hilton, Makio Ogawa
Cancer Research. 1988-03-01 - 14 citationsEfficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemiaSanthosh Sadashiv, Christie Hilton, Cyrus Khan, James Rossetti, Heather L. Benjamin
Cancer Medicine. 2014-12-01 - 5 citationsSafety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood...Cesar O. Freytes, Juan J. Toro, Rosa F. Yeh, Edward A. Stadtmauer, Voravit Ratanatharathorn
Biology of Blood and Marrow Transplantation. 2014-12-01